The Placental Basis of Fetal Growth Restriction.

Fetal growth restriction (FGR) Fetal vascular malperfusion (FVM) Intrauterine growth restriction (IUGR) Maternal vascular malperfusion (MVM) Placental dysfunction Placental growth factor (PlGF) Placental insufficiency Placental pathology

Journal

Obstetrics and gynecology clinics of North America
ISSN: 1558-0474
Titre abrégé: Obstet Gynecol Clin North Am
Pays: United States
ID NLM: 8709551

Informations de publication

Date de publication:
Mar 2020
Historique:
entrez: 4 2 2020
pubmed: 6 2 2020
medline: 12 11 2020
Statut: ppublish

Résumé

Placental dysfunction is a major contributing factor to fetal growth restriction. Placenta-mediated fetal growth restriction occurs through chronic fetal hypoxia owing to poor placental perfusion through a variety of mechanisms. Maternal vascular malperfusion is the most common placental disease contributing to fetal growth restriction; however, the role of rare placental diseases should not be overlooked. Although the features of maternal vascular malperfusion are identifiable on placental pathology, antepartum diagnostic methods are evolving. Placental imaging and uterine artery Doppler, used in conjunction with angiogenic growth factors (specifically placenta growth factor and soluble fms-like tyrosine kinase-1), play an increasingly important role.

Identifiants

pubmed: 32008673
pii: S0889-8545(19)30118-4
doi: 10.1016/j.ogc.2019.10.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

81-98

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Rebecca L Zur (RL)

Placenta Program, Maternal-Fetal Medicine Division, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.

John C Kingdom (JC)

Placenta Program, Maternal-Fetal Medicine Division, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. Electronic address: john.kingdom@sinaihealthsystem.ca.

W Tony Parks (WT)

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.

Sebastian R Hobson (SR)

Placenta Program, Maternal-Fetal Medicine Division, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH